Abstract
A critical appraisal and clinical application of Shelton E, Allegretti J, Stevens B et al. Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients. Inflammatory Bowel Diseases. 2015 Dec;21(12):2879-2885. doi:10.1097/mib.0000000000000561
DOI
10.22237/crp/1469047861
Recommended Citation
Kentor M. Vedolizumab should be the next line agent for the treatment of refractory Crohn's disease. Clin. Res. Pract. 2016 July 20;2(2):eP1138. doi: 10.22237/crp/1469047861
COinS
